Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > 0.27

<< Previous

Bullboard Posts

Next >>

Comment by biorunon Feb 10, 2022 7:32am

100 Views

Post# 34415563

RE:RE:RE:RE:RE:RE:0.27

How do you jump from what I said to all this? I have no idea when 1067 top 10 will announce and neither would anyone here or elsewhere. For 1067, PRC said the deal looks "imminent" and that is all we have to go on. Obviously some element of the market is speculating- we closed yesterday at 0.27!

The clues I was referring to relate to the updated info on the confirmation of number of partners etc from the table of pipelines- I will look closer this AM and be more explicit in my thinking here. Sorry Jimmy

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market